Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local Anesthetic Response in Ehlers-Danlos Syndrome
NCT05603741Phase 4Active, not recruiting
- Sponsor
- University of Calgary
- Start
- Nov 2022
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Lidocaine Hydrochloride Injection, without epinephrine in Ehlers-Danlos syndrome (EDS), sponsored by University of Calgary. Started Nov 2022; status: active, not recruiting.
02
Drugs
Lidocaine Hydrochloride Injection, without epinephrine
03
Conditions
Ehlers-Danlos syndrome (EDS)
Beyond the preview
Go deeper on NCT05603741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05603741.